Insiders At Medpace Holdings Sold US$525m In Stock, Alluding To Potential Weakness
Insiders At Medpace Holdings Sold US$525m In Stock, Alluding To Potential Weakness
In the last year, many Medpace Holdings, Inc. (NASDAQ:MEDP) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.
在过去的一年里,许多Medpace Holdings, Inc.(纳斯达克:MEDP)内部人士抛售了公司的大量股份,可能引起了股东的关注。在分析内部交易时,了解内部人士是在买入还是卖出通常更有价值,因为后者传递了模棱两可的信息。然而,如果有几位内部人士在特定时期内抛售股票,股东们应该更深入地观察。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.
虽然我们永远不会建议投资者仅基于公司董事已经做出的决策而做出决策,但同时我们认为完全忽略内部交易是愚蠢的。
Medpace Holdings Insider Transactions Over The Last Year
过去一年来,Medpace Holdings 内部交易
Over the last year, we can see that the biggest insider sale was by the Chairman & CEO, August Troendle, for US$82m worth of shares, at about US$413 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$363. So it may not shed much light on insider confidence at current levels.
在过去一年中,我们可以看到董事长兼首席执行官August Troendle进行了最大规模的内部人士卖出,价值8200万美元的股份,每股约413美元。一般来说,我们不喜欢看到内部人士抛售股票,但销售价格越低,我们就越担忧。值得一提的是,这次卖出的价格远高于当前股价363美元。所以这并没有对内部人士在当前水平上的信心提供太多线索。
In the last year Medpace Holdings insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在过去一年中,Medpace Holdings 内部人士没有购买任何公司股票。您可以在下图中看到过去一年内部交易(按公司和个人)的情况。如果您想准确了解谁以及何时以多少价格出售,请单击下面的图表!
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
如果你喜欢购买内部人员正在购买而不是销售的股票,那么你可能会喜欢这份免费的公司列表。(提示:它们中的大部分都被忽视了。)
Does Medpace Holdings Boast High Insider Ownership?
medpace控股公司是否拥有高比例的内部人员所有权?
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It's great to see that Medpace Holdings insiders own 18% of the company, worth about US$2.0b. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
许多投资者喜欢查看公司内部人员持有多少比例的股份。我们通常希望看到相当高比例的内部人员所有权。很高兴看到medpace控股公司的内部人员拥有该公司18%的股份,价值约20亿美元。大多数股东会很高兴看到这种内部人员所有权,因为这表明管理层的激励与其他股东的利益保持良好一致。
What Might The Insider Transactions At Medpace Holdings Tell Us?
medpace控股公司的内部交易可能告诉我们什么?
There haven't been any insider transactions in the last three months -- that doesn't mean much. It's great to see high levels of insider ownership, but looking back over the last year, we don't gain confidence from the Medpace Holdings insiders selling. Therefore, you should definitely take a look at this FREE report showing analyst forecasts for Medpace Holdings.
在过去三个月内没有内部交易--这并没有太多意义。很高兴看到较高比例的内部所有权,但回顾过去一年,我们并不认为medpace控股公司内部人员的卖出行为会让人有信心。因此,您绝对应该查看这份免费报告,其中列出了对medpace控股公司的分析师预测。
But note: Medpace Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但请注意:medpace控股可能不是最好的股票买入选择。因此,请看一下这份免费的股票列表,其中包含具有高roe和低债务的有趣公司。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。